Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
INOVIO to Present at Upcoming Scientific Conference | news.google.com • |
INOVIO to Present at Upcoming Scientific Conference | prnewswire.com • |
INOVIO to Present at Upcoming Scientific Conference | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-08 | 2024-06 | -1.15 | -1.19 | -0.04 | -3.48% |
2024-05-13 | 2024-03 | -1.08 | -1.31 | -0.23 | -21.30% |
2024-03-06 | 2023-12 | -1.58 | N/A | N/A | N/A |
2023-11-09 | 2023-09 | -1.56 | -1.08 | 0.48 | 30.77% |
2023-08-09 | 2023-06 | -1.68 | -1.56 | 0.12 | 7.14% |
2023-05-10 | 2023-03 | -1.68 | -1.92 | -0.24 | -14.29% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-05-10 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
2023-03-01 | RBC Capital | Upgrade | Sector Perform | |
2022-11-08 | Maxim Group | Downgrade | Buy | Hold |
2022-10-31 | B of A Securities | Downgrade | Neutral | Underperform |
2022-08-09 | RBC Capital | Upgrade | Sector Perform | |
2022-05-10 | Oppenheimer | Downgrade | Outperform | Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-05-14 | BENITO SIMON X | Director | 10.02K | Conversion of Exercise of derivative security |
2024-05-14 | DANSEY ROGER D | Director | 6.75K | Conversion of Exercise of derivative security |
2024-05-14 | HUMEAU LAURENT M | Officer | 24.34K | Conversion of Exercise of derivative security |
2024-05-14 | KIES PETER D | Chief Financial Officer | 24.74K | Conversion of Exercise of derivative security |
2024-05-14 | MILLER ANN CALBY M.D. | Director | 7.71K | Conversion of Exercise of derivative security |
2024-05-14 | SHEPARD JAY P. | Director | 7.04K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 20.07M | 8.96M | 7.49% |
2023-06-29 | Shaw D.E. & Co., Inc. | 7.60M | 3.39M | 2.84% |
2023-06-29 | Blackrock Inc. | 6.09M | 2.72M | 2.27% |
2023-06-29 | Renaissance Technologies, LLC | 5.44M | 2.43M | 2.03% |
2023-06-29 | Millennium Management Llc | 5.34M | 2.38M | 1.99% |
2023-06-29 | Jane Street Group, LLC | 3.20M | 1.43M | 1.19% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 8.26M | 3.69M | 3.08% |
2023-06-29 | Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 4.06M | 1.81M | 1.51% |
2023-06-29 | Vanguard Extended Market Index Fund | 3.35M | 1.50M | 1.25% |
2023-06-29 | Vanguard Strategic Equity Fund | 3.00M | 1.34M | 1.12% |
2023-08-30 | iShares NASDAQ Biotechnology ETF | 1.88M | 844.39K | 0.70% |
2023-05-30 | Fidelity Extended Market Index Fund | 1.27M | 761.76K | 0.47% |
Dividend | Date |
---|---|
0.0057 | 2017-09-28 |
0.0057 | 2017-08-29 |
0.0057 | 2017-07-27 |
0.0057 | 2017-06-28 |
Split | Date |
---|---|
1 : 12 | 2024-01-25 |
1 : 4 | 2014-06-06 |
1 : 4 | 2014-06-05 |
0.25 : 1 | 2004-09-13 |
-
-
any upcoming news?
-
This will recover to $18-20 range by next week easy
-
$INO. GO BABY !!!! https://apple.news/A5ZU-h3jVQDayqJ8Z4jCmpQ
-
$INO.... Fu$&@-“:&;$;!:
-
$INO thanks for the discount!!!! Just loaded up !!!!!
-
Fuck me with a hot ladle
-
-
Holy crap this is a falling knife
-
Vaccine specialist Vaxart (VXRT reported 2Q20 earnings last week, but since its vaccine candidates are all in development, the results themselves were of little importance. More pertinent for investors were updates on the pipeline’s progress. Specifically, Vaxart’s COVID-19 oral vaccine candidate.
As the only oral vaccine to be selected for inclusion in the government’s Operation Warp Speed (OWS) program, Vaxart’s offering has shown promise in pre-clinical trials, with a Phase 1 study expected to begin sometime in 2H20.
While Vaxart’s incredible rise this year (shares are up by over 2,500%) has been solely COVID-driven, the company has other vaccines in development. These include its H1N1 influenza oral tablet vaccine, which recently progressed through a BARDA-funded Phase 2 challenge study evaluating its efficacy against Sanofi's Fluzone. This study yielded positive results.
Additionally, Vaxart has established a working relationship with vaccine leader Janssen, who will make use of Vaxart’s proprietaryVAAST platform and its R&D skills to develop immunogenic oral vaccines.
-
Look VXRT. It’s jumping
-
16$ incoming
-
Last chance to close your short position
-
Closes over $16 today
-
If your scared go to church or get the hell out of the stock. To much crying going on.
-
Fuck you
-
-
-
If anybody in here thinks that it’s a better decision to go to Johnson & Johnson now, feel free to make small gains. I’m here for the big news.
-
This turd repels the $21 mark.
-
INOVIO to Present at Upcoming Scientific Conference
news.google.com • -
INOVIO to Present at Upcoming Scientific Conference
prnewswire.com • -
INOVIO to Present at Upcoming Scientific Conference
news.google.com • -
(INO) Proactive Strategies
news.google.com • -
Inovio Pharmaceuticals, Inc. (INO) Q2 2024 Earnings Call Transcript
seekingalpha.com • -
INOVIO Reports Inducement Grant Under Inducement Plan
prnewswire.com • -
INOVIO Reports Inducement Grant Under Inducement Plan
prnewswire.com • -
INOVIO Added to Russell 2000® Index Effective July 1, 2024
prnewswire.com • -
INOVIO Reports Inducement Grants Under Inducement Plan
prnewswire.com • -
Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Call Transcript
seekingalpha.com •